ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cognitive Impairment Disorders Treatment Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-26Y11700
Home | Market Reports | Health| Mental Health
Global Cognitive Impairment Disorders Treatment Market Research Report 2022
BUY CHAPTERS

Global Cognitive Impairment Disorders Treatment Market Research Report 2025

Code: QYRE-Auto-26Y11700
Report
March 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Bristol–Myers Squibb
Pfizer Inc
Minerva Neurosciences
Intra-Cellular Therapies
Lundbeck
AB Science SA
AbbVie
CHA Bio & Diostech Co., Ltd.
Eisai Co Ltd
GlaxoSmithKline PLC
Grifols SA
Immungenetics AG
Otsuka Holdings Co Ltd
Merck& Co. Inc
Kyowa Hakko Kirin Co Ltd
Avineuro Pharmaceuticals
SyneuRx
Echo Pharmaceuticals BV
Eli Lilly and Company

Cognitive Impairment Disorders Treatment Market Size

The global market for Cognitive Impairment Disorders Treatment was valued at US$ 177 million in the year 2024 and is projected to reach a revised size of US$ 279 million by 2031, growing at a CAGR of 6.8% during the forecast period.

Cognitive Impairment Disorders Treatment Market

Cognitive Impairment Disorders Treatment Market

Cognitive impairment disorders treatment refers to interventions and therapeutic approaches aimed at managing and improving cognitive function in individuals affected by cognitive impairment disorders. Cognitive impairment disorders involve deficits in cognitive functions, including memory, attention, language, executive function, and problem-solving. These disorders can range from mild cognitive impairment (MCI) to more severe conditions such as Alzheimer"s disease and other types of dementia.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cognitive Impairment Disorders Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cognitive Impairment Disorders Treatment.
The Cognitive Impairment Disorders Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cognitive Impairment Disorders Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cognitive Impairment Disorders Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Cognitive Impairment Disorders Treatment Market Report

Report Metric Details
Report Name Cognitive Impairment Disorders Treatment Market
Accounted market size in year US$ 177 million
Forecasted market size in 2031 US$ 279 million
CAGR 6.8%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Antiepileptic Drugs Cognitive Impairment Disorders Treatment
  • Antipsychotics Drugs Cognitive Impairment Disorders Treatment
Segment by Application
  • Hospital Pharmacies
  • Specialty Clinics
  • Retail Pharmacies
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx, Lundbeck, AB Science SA, AbbVie Inc, CHA Bio & Diostech Co Ltd, Echo Pharmaceuticals BV, Eisai Co Ltd, GlaxoSmithKline Plc, Grifols SA, Immungenetics AG, Otsuka Holdings Co Ltd, Merck & Co Inc, Kyowa Hakko Kirin Co Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Cognitive Impairment Disorders Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Cognitive Impairment Disorders Treatment Market growing?

Ans: The Cognitive Impairment Disorders Treatment Market witnessing a CAGR of 6.8% during the forecast period 2025-2031.

What is the Cognitive Impairment Disorders Treatment Market size in 2031?

Ans: The Cognitive Impairment Disorders Treatment Market size in 2031 will be US$ 279 million.

Who are the main players in the Cognitive Impairment Disorders Treatment Market report?

Ans: The main players in the Cognitive Impairment Disorders Treatment Market are Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Minerva Neurosciences, Intra-Cellular Therapies, Avineuro Pharmaceuticals, SyneuRx, Lundbeck, AB Science SA, AbbVie Inc, CHA Bio & Diostech Co Ltd, Echo Pharmaceuticals BV, Eisai Co Ltd, GlaxoSmithKline Plc, Grifols SA, Immungenetics AG, Otsuka Holdings Co Ltd, Merck & Co Inc, Kyowa Hakko Kirin Co Ltd

What are the Application segmentation covered in the Cognitive Impairment Disorders Treatment Market report?

Ans: The Applications covered in the Cognitive Impairment Disorders Treatment Market report are Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, Others

What are the Type segmentation covered in the Cognitive Impairment Disorders Treatment Market report?

Ans: The Types covered in the Cognitive Impairment Disorders Treatment Market report are Antiepileptic Drugs Cognitive Impairment Disorders Treatment, Antipsychotics Drugs Cognitive Impairment Disorders Treatment

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cognitive Impairment Disorders Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antiepileptic Drugs Cognitive Impairment Disorders Treatment
1.2.3 Antipsychotics Drugs Cognitive Impairment Disorders Treatment
1.3 Market by Application
1.3.1 Global Cognitive Impairment Disorders Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Specialty Clinics
1.3.4 Retail Pharmacies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cognitive Impairment Disorders Treatment Market Perspective (2020-2031)
2.2 Global Cognitive Impairment Disorders Treatment Growth Trends by Region
2.2.1 Global Cognitive Impairment Disorders Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cognitive Impairment Disorders Treatment Historic Market Size by Region (2020-2025)
2.2.3 Cognitive Impairment Disorders Treatment Forecasted Market Size by Region (2026-2031)
2.3 Cognitive Impairment Disorders Treatment Market Dynamics
2.3.1 Cognitive Impairment Disorders Treatment Industry Trends
2.3.2 Cognitive Impairment Disorders Treatment Market Drivers
2.3.3 Cognitive Impairment Disorders Treatment Market Challenges
2.3.4 Cognitive Impairment Disorders Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cognitive Impairment Disorders Treatment Players by Revenue
3.1.1 Global Top Cognitive Impairment Disorders Treatment Players by Revenue (2020-2025)
3.1.2 Global Cognitive Impairment Disorders Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Cognitive Impairment Disorders Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cognitive Impairment Disorders Treatment Revenue
3.4 Global Cognitive Impairment Disorders Treatment Market Concentration Ratio
3.4.1 Global Cognitive Impairment Disorders Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cognitive Impairment Disorders Treatment Revenue in 2024
3.5 Global Key Players of Cognitive Impairment Disorders Treatment Head office and Area Served
3.6 Global Key Players of Cognitive Impairment Disorders Treatment, Product and Application
3.7 Global Key Players of Cognitive Impairment Disorders Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cognitive Impairment Disorders Treatment Breakdown Data by Type
4.1 Global Cognitive Impairment Disorders Treatment Historic Market Size by Type (2020-2025)
4.2 Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Type (2026-2031)
5 Cognitive Impairment Disorders Treatment Breakdown Data by Application
5.1 Global Cognitive Impairment Disorders Treatment Historic Market Size by Application (2020-2025)
5.2 Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cognitive Impairment Disorders Treatment Market Size (2020-2031)
6.2 North America Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025)
6.4 North America Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cognitive Impairment Disorders Treatment Market Size (2020-2031)
7.2 Europe Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025)
7.4 Europe Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size (2020-2031)
8.2 Asia-Pacific Cognitive Impairment Disorders Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cognitive Impairment Disorders Treatment Market Size (2020-2031)
9.2 Latin America Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025)
9.4 Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size (2020-2031)
10.2 Middle East & Africa Cognitive Impairment Disorders Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Details
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Cognitive Impairment Disorders Treatment Introduction
11.1.4 Eli Lilly and Company Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.1.5 Eli Lilly and Company Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Cognitive Impairment Disorders Treatment Introduction
11.2.4 AstraZeneca Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Cognitive Impairment Disorders Treatment Introduction
11.3.4 Bristol-Myers Squibb Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Cognitive Impairment Disorders Treatment Introduction
11.4.4 Pfizer Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.4.5 Pfizer Recent Development
11.5 Minerva Neurosciences
11.5.1 Minerva Neurosciences Company Details
11.5.2 Minerva Neurosciences Business Overview
11.5.3 Minerva Neurosciences Cognitive Impairment Disorders Treatment Introduction
11.5.4 Minerva Neurosciences Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.5.5 Minerva Neurosciences Recent Development
11.6 Intra-Cellular Therapies
11.6.1 Intra-Cellular Therapies Company Details
11.6.2 Intra-Cellular Therapies Business Overview
11.6.3 Intra-Cellular Therapies Cognitive Impairment Disorders Treatment Introduction
11.6.4 Intra-Cellular Therapies Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.6.5 Intra-Cellular Therapies Recent Development
11.7 Avineuro Pharmaceuticals
11.7.1 Avineuro Pharmaceuticals Company Details
11.7.2 Avineuro Pharmaceuticals Business Overview
11.7.3 Avineuro Pharmaceuticals Cognitive Impairment Disorders Treatment Introduction
11.7.4 Avineuro Pharmaceuticals Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.7.5 Avineuro Pharmaceuticals Recent Development
11.8 SyneuRx
11.8.1 SyneuRx Company Details
11.8.2 SyneuRx Business Overview
11.8.3 SyneuRx Cognitive Impairment Disorders Treatment Introduction
11.8.4 SyneuRx Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.8.5 SyneuRx Recent Development
11.9 Lundbeck
11.9.1 Lundbeck Company Details
11.9.2 Lundbeck Business Overview
11.9.3 Lundbeck Cognitive Impairment Disorders Treatment Introduction
11.9.4 Lundbeck Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.9.5 Lundbeck Recent Development
11.10 AB Science SA
11.10.1 AB Science SA Company Details
11.10.2 AB Science SA Business Overview
11.10.3 AB Science SA Cognitive Impairment Disorders Treatment Introduction
11.10.4 AB Science SA Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.10.5 AB Science SA Recent Development
11.11 AbbVie Inc
11.11.1 AbbVie Inc Company Details
11.11.2 AbbVie Inc Business Overview
11.11.3 AbbVie Inc Cognitive Impairment Disorders Treatment Introduction
11.11.4 AbbVie Inc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.11.5 AbbVie Inc Recent Development
11.12 CHA Bio & Diostech Co Ltd
11.12.1 CHA Bio & Diostech Co Ltd Company Details
11.12.2 CHA Bio & Diostech Co Ltd Business Overview
11.12.3 CHA Bio & Diostech Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.12.4 CHA Bio & Diostech Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.12.5 CHA Bio & Diostech Co Ltd Recent Development
11.13 Echo Pharmaceuticals BV
11.13.1 Echo Pharmaceuticals BV Company Details
11.13.2 Echo Pharmaceuticals BV Business Overview
11.13.3 Echo Pharmaceuticals BV Cognitive Impairment Disorders Treatment Introduction
11.13.4 Echo Pharmaceuticals BV Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.13.5 Echo Pharmaceuticals BV Recent Development
11.14 Eisai Co Ltd
11.14.1 Eisai Co Ltd Company Details
11.14.2 Eisai Co Ltd Business Overview
11.14.3 Eisai Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.14.4 Eisai Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.14.5 Eisai Co Ltd Recent Development
11.15 GlaxoSmithKline Plc
11.15.1 GlaxoSmithKline Plc Company Details
11.15.2 GlaxoSmithKline Plc Business Overview
11.15.3 GlaxoSmithKline Plc Cognitive Impairment Disorders Treatment Introduction
11.15.4 GlaxoSmithKline Plc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.15.5 GlaxoSmithKline Plc Recent Development
11.16 Grifols SA
11.16.1 Grifols SA Company Details
11.16.2 Grifols SA Business Overview
11.16.3 Grifols SA Cognitive Impairment Disorders Treatment Introduction
11.16.4 Grifols SA Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.16.5 Grifols SA Recent Development
11.17 Immungenetics AG
11.17.1 Immungenetics AG Company Details
11.17.2 Immungenetics AG Business Overview
11.17.3 Immungenetics AG Cognitive Impairment Disorders Treatment Introduction
11.17.4 Immungenetics AG Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.17.5 Immungenetics AG Recent Development
11.18 Otsuka Holdings Co Ltd
11.18.1 Otsuka Holdings Co Ltd Company Details
11.18.2 Otsuka Holdings Co Ltd Business Overview
11.18.3 Otsuka Holdings Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.18.4 Otsuka Holdings Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.18.5 Otsuka Holdings Co Ltd Recent Development
11.19 Merck & Co Inc
11.19.1 Merck & Co Inc Company Details
11.19.2 Merck & Co Inc Business Overview
11.19.3 Merck & Co Inc Cognitive Impairment Disorders Treatment Introduction
11.19.4 Merck & Co Inc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.19.5 Merck & Co Inc Recent Development
11.20 Kyowa Hakko Kirin Co Ltd
11.20.1 Kyowa Hakko Kirin Co Ltd Company Details
11.20.2 Kyowa Hakko Kirin Co Ltd Business Overview
11.20.3 Kyowa Hakko Kirin Co Ltd Cognitive Impairment Disorders Treatment Introduction
11.20.4 Kyowa Hakko Kirin Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025)
11.20.5 Kyowa Hakko Kirin Co Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Bristol–Myers Squibb
Pfizer Inc
Minerva Neurosciences
Intra-Cellular Therapies
Lundbeck
AB Science SA
AbbVie
CHA Bio & Diostech Co., Ltd.
Eisai Co Ltd
GlaxoSmithKline PLC
Grifols SA
Immungenetics AG
Otsuka Holdings Co Ltd
Merck& Co. Inc
Kyowa Hakko Kirin Co Ltd
Avineuro Pharmaceuticals
SyneuRx
Echo Pharmaceuticals BV
Eli Lilly and Company
List of Tables
 Table 1. Global Cognitive Impairment Disorders Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antiepileptic Drugs Cognitive Impairment Disorders Treatment
 Table 3. Key Players of Antipsychotics Drugs Cognitive Impairment Disorders Treatment
 Table 4. Global Cognitive Impairment Disorders Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Cognitive Impairment Disorders Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Cognitive Impairment Disorders Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Cognitive Impairment Disorders Treatment Market Share by Region (2020-2025)
 Table 8. Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Cognitive Impairment Disorders Treatment Market Share by Region (2026-2031)
 Table 10. Cognitive Impairment Disorders Treatment Market Trends
 Table 11. Cognitive Impairment Disorders Treatment Market Drivers
 Table 12. Cognitive Impairment Disorders Treatment Market Challenges
 Table 13. Cognitive Impairment Disorders Treatment Market Restraints
 Table 14. Global Cognitive Impairment Disorders Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Cognitive Impairment Disorders Treatment Market Share by Players (2020-2025)
 Table 16. Global Top Cognitive Impairment Disorders Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cognitive Impairment Disorders Treatment as of 2024)
 Table 17. Ranking of Global Top Cognitive Impairment Disorders Treatment Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Cognitive Impairment Disorders Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Cognitive Impairment Disorders Treatment, Headquarters and Area Served
 Table 20. Global Key Players of Cognitive Impairment Disorders Treatment, Product and Application
 Table 21. Global Key Players of Cognitive Impairment Disorders Treatment, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Cognitive Impairment Disorders Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Cognitive Impairment Disorders Treatment Revenue Market Share by Type (2020-2025)
 Table 25. Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Cognitive Impairment Disorders Treatment Revenue Market Share by Type (2026-2031)
 Table 27. Global Cognitive Impairment Disorders Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Cognitive Impairment Disorders Treatment Revenue Market Share by Application (2020-2025)
 Table 29. Global Cognitive Impairment Disorders Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Cognitive Impairment Disorders Treatment Revenue Market Share by Application (2026-2031)
 Table 31. North America Cognitive Impairment Disorders Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Cognitive Impairment Disorders Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Cognitive Impairment Disorders Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Cognitive Impairment Disorders Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Cognitive Impairment Disorders Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Cognitive Impairment Disorders Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Cognitive Impairment Disorders Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Eli Lilly and Company Company Details
 Table 47. Eli Lilly and Company Business Overview
 Table 48. Eli Lilly and Company Cognitive Impairment Disorders Treatment Product
 Table 49. Eli Lilly and Company Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 50. Eli Lilly and Company Recent Development
 Table 51. AstraZeneca Company Details
 Table 52. AstraZeneca Business Overview
 Table 53. AstraZeneca Cognitive Impairment Disorders Treatment Product
 Table 54. AstraZeneca Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 55. AstraZeneca Recent Development
 Table 56. Bristol-Myers Squibb Company Details
 Table 57. Bristol-Myers Squibb Business Overview
 Table 58. Bristol-Myers Squibb Cognitive Impairment Disorders Treatment Product
 Table 59. Bristol-Myers Squibb Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 60. Bristol-Myers Squibb Recent Development
 Table 61. Pfizer Company Details
 Table 62. Pfizer Business Overview
 Table 63. Pfizer Cognitive Impairment Disorders Treatment Product
 Table 64. Pfizer Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 65. Pfizer Recent Development
 Table 66. Minerva Neurosciences Company Details
 Table 67. Minerva Neurosciences Business Overview
 Table 68. Minerva Neurosciences Cognitive Impairment Disorders Treatment Product
 Table 69. Minerva Neurosciences Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 70. Minerva Neurosciences Recent Development
 Table 71. Intra-Cellular Therapies Company Details
 Table 72. Intra-Cellular Therapies Business Overview
 Table 73. Intra-Cellular Therapies Cognitive Impairment Disorders Treatment Product
 Table 74. Intra-Cellular Therapies Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 75. Intra-Cellular Therapies Recent Development
 Table 76. Avineuro Pharmaceuticals Company Details
 Table 77. Avineuro Pharmaceuticals Business Overview
 Table 78. Avineuro Pharmaceuticals Cognitive Impairment Disorders Treatment Product
 Table 79. Avineuro Pharmaceuticals Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 80. Avineuro Pharmaceuticals Recent Development
 Table 81. SyneuRx Company Details
 Table 82. SyneuRx Business Overview
 Table 83. SyneuRx Cognitive Impairment Disorders Treatment Product
 Table 84. SyneuRx Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 85. SyneuRx Recent Development
 Table 86. Lundbeck Company Details
 Table 87. Lundbeck Business Overview
 Table 88. Lundbeck Cognitive Impairment Disorders Treatment Product
 Table 89. Lundbeck Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 90. Lundbeck Recent Development
 Table 91. AB Science SA Company Details
 Table 92. AB Science SA Business Overview
 Table 93. AB Science SA Cognitive Impairment Disorders Treatment Product
 Table 94. AB Science SA Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 95. AB Science SA Recent Development
 Table 96. AbbVie Inc Company Details
 Table 97. AbbVie Inc Business Overview
 Table 98. AbbVie Inc Cognitive Impairment Disorders Treatment Product
 Table 99. AbbVie Inc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 100. AbbVie Inc Recent Development
 Table 101. CHA Bio & Diostech Co Ltd Company Details
 Table 102. CHA Bio & Diostech Co Ltd Business Overview
 Table 103. CHA Bio & Diostech Co Ltd Cognitive Impairment Disorders Treatment Product
 Table 104. CHA Bio & Diostech Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 105. CHA Bio & Diostech Co Ltd Recent Development
 Table 106. Echo Pharmaceuticals BV Company Details
 Table 107. Echo Pharmaceuticals BV Business Overview
 Table 108. Echo Pharmaceuticals BV Cognitive Impairment Disorders Treatment Product
 Table 109. Echo Pharmaceuticals BV Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 110. Echo Pharmaceuticals BV Recent Development
 Table 111. Eisai Co Ltd Company Details
 Table 112. Eisai Co Ltd Business Overview
 Table 113. Eisai Co Ltd Cognitive Impairment Disorders Treatment Product
 Table 114. Eisai Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 115. Eisai Co Ltd Recent Development
 Table 116. GlaxoSmithKline Plc Company Details
 Table 117. GlaxoSmithKline Plc Business Overview
 Table 118. GlaxoSmithKline Plc Cognitive Impairment Disorders Treatment Product
 Table 119. GlaxoSmithKline Plc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 120. GlaxoSmithKline Plc Recent Development
 Table 121. Grifols SA Company Details
 Table 122. Grifols SA Business Overview
 Table 123. Grifols SA Cognitive Impairment Disorders Treatment Product
 Table 124. Grifols SA Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 125. Grifols SA Recent Development
 Table 126. Immungenetics AG Company Details
 Table 127. Immungenetics AG Business Overview
 Table 128. Immungenetics AG Cognitive Impairment Disorders Treatment Product
 Table 129. Immungenetics AG Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 130. Immungenetics AG Recent Development
 Table 131. Otsuka Holdings Co Ltd Company Details
 Table 132. Otsuka Holdings Co Ltd Business Overview
 Table 133. Otsuka Holdings Co Ltd Cognitive Impairment Disorders Treatment Product
 Table 134. Otsuka Holdings Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 135. Otsuka Holdings Co Ltd Recent Development
 Table 136. Merck & Co Inc Company Details
 Table 137. Merck & Co Inc Business Overview
 Table 138. Merck & Co Inc Cognitive Impairment Disorders Treatment Product
 Table 139. Merck & Co Inc Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 140. Merck & Co Inc Recent Development
 Table 141. Kyowa Hakko Kirin Co Ltd Company Details
 Table 142. Kyowa Hakko Kirin Co Ltd Business Overview
 Table 143. Kyowa Hakko Kirin Co Ltd Cognitive Impairment Disorders Treatment Product
 Table 144. Kyowa Hakko Kirin Co Ltd Revenue in Cognitive Impairment Disorders Treatment Business (2020-2025) & (US$ Million)
 Table 145. Kyowa Hakko Kirin Co Ltd Recent Development
 Table 146. Research Programs/Design for This Report
 Table 147. Key Data Information from Secondary Sources
 Table 148. Key Data Information from Primary Sources
 Table 149. Authors List of This Report


List of Figures
 Figure 1. Cognitive Impairment Disorders Treatment Picture
 Figure 2. Global Cognitive Impairment Disorders Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Cognitive Impairment Disorders Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Antiepileptic Drugs Cognitive Impairment Disorders Treatment Features
 Figure 5. Antipsychotics Drugs Cognitive Impairment Disorders Treatment Features
 Figure 6. Global Cognitive Impairment Disorders Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Cognitive Impairment Disorders Treatment Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Pharmacies Case Studies
 Figure 9. Specialty Clinics Case Studies
 Figure 10. Retail Pharmacies Case Studies
 Figure 11. Others Case Studies
 Figure 12. Cognitive Impairment Disorders Treatment Report Years Considered
 Figure 13. Global Cognitive Impairment Disorders Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Cognitive Impairment Disorders Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Cognitive Impairment Disorders Treatment Market Share by Region: 2024 VS 2031
 Figure 16. Global Cognitive Impairment Disorders Treatment Market Share by Players in 2024
 Figure 17. Global Top Cognitive Impairment Disorders Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cognitive Impairment Disorders Treatment as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Cognitive Impairment Disorders Treatment Revenue in 2024
 Figure 19. North America Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Cognitive Impairment Disorders Treatment Market Share by Country (2020-2031)
 Figure 21. United States Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Cognitive Impairment Disorders Treatment Market Share by Country (2020-2031)
 Figure 25. Germany Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Cognitive Impairment Disorders Treatment Market Share by Region (2020-2031)
 Figure 33. China Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Cognitive Impairment Disorders Treatment Market Share by Country (2020-2031)
 Figure 41. Mexico Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Cognitive Impairment Disorders Treatment Market Share by Country (2020-2031)
 Figure 45. Turkey Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Cognitive Impairment Disorders Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Eli Lilly and Company Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 49. AstraZeneca Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 51. Pfizer Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 52. Minerva Neurosciences Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 53. Intra-Cellular Therapies Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 54. Avineuro Pharmaceuticals Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 55. SyneuRx Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 56. Lundbeck Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 57. AB Science SA Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 58. AbbVie Inc Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 59. CHA Bio & Diostech Co Ltd Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 60. Echo Pharmaceuticals BV Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 61. Eisai Co Ltd Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 62. GlaxoSmithKline Plc Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 63. Grifols SA Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 64. Immungenetics AG Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 65. Otsuka Holdings Co Ltd Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 66. Merck & Co Inc Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 67. Kyowa Hakko Kirin Co Ltd Revenue Growth Rate in Cognitive Impairment Disorders Treatment Business (2020-2025)
 Figure 68. Bottom-up and Top-down Approaches for This Report
 Figure 69. Data Triangulation
 Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Cognitive Rehabilitation Training and Evaluation System Market Research Report 2025
Global Cognitive Impairment Rehabilitation Equipment Market Research Report 2024
Global Cognitive Rehabilitation and Assessment Software Market Research Report 2024
Global Alzheimer s Disease Therapeutics and Diagnostics Market Insights Forecast to 2030
Global Neurocognitive Assessment and Rehabilitation Market Research Report 2024
Global Cognitive Assessment and Training Healthcare Market Research Report 2025
Dementia and Alzheimer s Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Alzheimer s Disease Treatments Market Research Report 2024
Global Alzheimer Treatment Drug Market Research Report 2025
Treatment for Syndromes of Dementia and Movement Disorders Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Vascular Dementia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Frontotemporal Dementia Treatment Market Research Report 2025
Amnestic Disorders Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Learning Disability Treatment Market Insights Forecast to 2030
Global Cognitive Supplement Market Research Report 2024
Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025
Global Neurodiversity Cognitive Assessment Software Market Research Report 2024
Global Dementia Care APP Market Insights Forecast to 2030
Global Cognitive Behavioral Therapy Service Market Research Report 2024
Global Anti amyloid Therapy Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions